Q1 CAR-T Therapy Sales See Up to 146% Surge

With leading pharmaceutical companies releasing their Q1 2025 financial reports, GuideView has compiled an overview of global sales figures for six approved CAR-T cell therapies. The latest data reveal that some therapies experienced significant commercial growth, with the highest sales increase reaching an impressive 146% year-over-year.

Kymriah Sales Decline for Novartis

Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) reported sales of $100 million in Q1 2025, reflecting a 17% decline compared to the same period last year. Targeting the CD19 antigen, Kymriah was first approved by the U.S. FDA in 2017. It is indicated for pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia (r/r ALL), as well as adult patients with r/r diffuse large B-cell lymphoma (DLBCL) and r/r follicular lymphoma (FL).

As stated in the original report: “2025Q1 sales: $100 million (-17%)”.

Yescarta Posts Modest Growth

Developed by Kite Pharma and Gilead Sciences, Yescarta (axicabtagene ciloleucel) achieved Q1 2025 sales of $386 million, representing a 1.6% year-over-year increase. Like Kymriah, Yescarta targets CD19 and was approved in 2017. It is approved for r/r large B-cell lymphoma (LBCL) and r/r follicular lymphoma (FL).

From the original report: “2025Q1 sales: $386 million (+1.6%)”.

Tecartus Sees Sales Drop

Tecartus (brexucabtagene autoleucel), another product from Kite/Gilead, focuses on adult patients with r/r mantle cell lymphoma (MCL) and B-cell precursor acute lymphoblastic leukemia (B-ALL). Despite a price tag of $373,000, Tecartus posted Q1 2025 sales of $78 million, down 22% year-over-year.

Original data: “2025Q1 sales: $78 million (-22%)”.

Breyanzi Leads CAR-T Market Growth

Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) posted the highest growth among CAR-T therapies, with Q1 2025 sales reaching $263 million—a remarkable 146% increase from the same period last year. Approved in 2021, the therapy targets CD19 and is indicated for relapsed or refractory large B-cell lymphoma.

Original text: “2025Q1 sales: $263 million (+146%)”.

Abecma Maintains Steady Momentum

Abecma (idecabtagene vicleucel), co-developed by Bristol Myers Squibb and bluebird bio, targets BCMA and treats relapsed or refractory multiple myeloma (r/r MM). It generated $103 million in Q1 2025, showing a solid 26% year-over-year increase.

Original: “2025Q1 sales: $103 million (+26%)”.

Carvykti Delivers Explosive Growth

Carvykti (ciltacabtagene autoleucel), developed by Legend Biotech and Johnson & Johnson, also targets BCMA and treats r/r multiple myeloma. In Q1 2025, it posted sales of $369 million—a 135% year-over-year increase, ranking second in total CAR-T sales.

From the original: “2025Q1 sales: $369 million (+135%)”.

Highlights

• All six commercialized CAR-T therapies showed mixed sales performance in Q1 2025.
• Breyanzi saw the highest year-over-year growth at 146%.
• Carvykti followed closely with a 135% increase in sales.
• Kymriah and Tecartus posted declines of 17% and 22%, respectively.
• Yescarta and Abecma showed moderate gains at 1.6% and 26%.
• BCMA-targeted therapies (Abecma and Carvykti) outperformed their CD19-targeted counterparts in growth.